Reviva Pharmaceuticals (RVPH) Competitors $0.27 -0.15 (-36.43%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.27 +0.00 (+0.15%) As of 09/19/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. PYXS, FATE, BMEA, PLRX, EQ, IFRX, VTGN, TCRX, ONCY, and HLVXShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Pyxis Oncology (PYXS), Fate Therapeutics (FATE), Biomea Fusion (BMEA), Pliant Therapeutics (PLRX), Equillium (EQ), InflaRx (IFRX), VistaGen Therapeutics (VTGN), TScan Therapeutics (TCRX), Oncolytics Biotech (ONCY), and HilleVax (HLVX). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors Pyxis Oncology Fate Therapeutics Biomea Fusion Pliant Therapeutics Equillium InflaRx VistaGen Therapeutics TScan Therapeutics Oncolytics Biotech HilleVax Reviva Pharmaceuticals (NASDAQ:RVPH) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Which has more volatility & risk, RVPH or PYXS? Reviva Pharmaceuticals has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Is RVPH or PYXS more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Pyxis Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -259.17% Pyxis Oncology N/A -68.56%-52.14% Do analysts rate RVPH or PYXS? Reviva Pharmaceuticals presently has a consensus price target of $5.33, suggesting a potential upside of 1,900.50%. Pyxis Oncology has a consensus price target of $7.75, suggesting a potential upside of 244.44%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Pyxis Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Pyxis Oncology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders & institutionals hold more shares of RVPH or PYXS? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 10.6% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer RVPH or PYXS? In the previous week, Reviva Pharmaceuticals had 9 more articles in the media than Pyxis Oncology. MarketBeat recorded 9 mentions for Reviva Pharmaceuticals and 0 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.00 beat Reviva Pharmaceuticals' score of -0.33 indicating that Pyxis Oncology is being referred to more favorably in the news media. Company Overall Sentiment Reviva Pharmaceuticals Neutral Pyxis Oncology Positive Which has preferable valuation & earnings, RVPH or PYXS? Reviva Pharmaceuticals has higher earnings, but lower revenue than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$29.92M-$0.65-0.41Pyxis Oncology$2.82M49.48-$77.33M-$1.60-1.41 SummaryReviva Pharmaceuticals beats Pyxis Oncology on 11 of the 15 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.13M$2.57B$5.79B$10.47BDividend YieldN/A55.05%5.61%4.61%P/E Ratio-0.4123.0280.5026.80Price / SalesN/A621.51532.45123.16Price / CashN/A172.2337.6661.43Price / Book13.335.3515.756.39Net Income-$29.92M$32.95M$3.30B$271.80M7 Day Performance-39.72%0.90%5.36%3.49%1 Month Performance-48.65%5.76%8.10%9.90%1 Year Performance-79.17%-3.43%81.36%28.62% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals3.1694 of 5 stars$0.27-36.4%$5.33+1,900.5%-79.6%$18.13MN/A-0.415News CoverageAnalyst ForecastGap DownHigh Trading VolumePYXSPyxis Oncology2.3376 of 5 stars$1.96+2.6%$7.75+295.4%-38.9%$118.46M$16.15M-1.2260Gap UpHigh Trading VolumeFATEFate Therapeutics4.0043 of 5 stars$0.97-4.4%$3.30+241.6%-75.9%$116.48M$13.63M-0.67550Positive NewsBMEABiomea Fusion3.4222 of 5 stars$1.81-5.7%$14.80+717.7%-77.6%$114.26MN/A-0.6050PLRXPliant Therapeutics4.105 of 5 stars$1.73-7.0%$8.19+373.3%-88.7%$114.18M$1.58M-0.5190Positive NewsEQEquillium0.8592 of 5 stars$1.88-1.6%$1.00-46.8%+67.8%$113.65M$41.10M-3.3640Gap UpIFRXInflaRx3.2385 of 5 stars$1.58-4.2%$6.20+292.4%-11.8%$110.77M$180K-1.9760Positive NewsGap DownVTGNVistaGen Therapeutics1.2002 of 5 stars$3.48-2.0%N/A-0.7%$108.92M$490K-1.9640TCRXTScan Therapeutics2.5598 of 5 stars$1.88-1.6%$7.80+314.9%-68.3%$108.39M$2.82M-1.72100Positive NewsONCYOncolytics Biotech2.2709 of 5 stars$1.28+20.8%$5.00+290.6%+43.2%$106.38MN/A-4.7430News CoverageAnalyst RevisionGap UpHigh Trading VolumeHLVXHilleVax1.4714 of 5 stars$2.09-0.5%$2.00-4.3%N/A$105.30MN/A-1.4620News CoverageAnalyst UpgradeShort Interest ↑ Related Companies and Tools Related Companies PYXS Alternatives FATE Alternatives BMEA Alternatives PLRX Alternatives EQ Alternatives IFRX Alternatives VTGN Alternatives TCRX Alternatives ONCY Alternatives HLVX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
